Immune modifiers in the treatment of bladder cancer
Morales, A.
Progress in Clinical and Biological Research 350: 25-33
1990
ISSN/ISBN: 0361-7742 PMID: 2201046 Document Number: 353639
Document emailed within 1 workday
Related Documents
Abdel-Rahman, S.Z.; Anwar, W.A.; Abdel-Aal, W.E.; Mostafa, H.M.; Au, W.W. 1998: GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer Cancer Detection and Prevention 22(2): 129-138Zlotta, A.R.; Schulman, C.C. 2000: Biological response modifiers for the treatment of superficial bladder tumors European Urology 37(Suppl): 10-15
Shekarsarai, H.; Zlotta, A.R.; Drowart, A.; Van Vooren, J.P.; De Cock, M.; Pirson, M.; Palfliet, K.; Jurion, F.; Vanonckelen, A.; Simon, J.; Schulman, C.C.; Huygen, K. 1997: The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG Acta Urologica Belgica 65(1): 1-4
Okawa, T.; Goto, M.; Kita, M. 1987: Radiotherapy combined with BRM (biological response modifiers) in the treatment of cancer Gan no Rinsho. Japan Journal of Cancer Clinics 33(10): 1253-1256
Pawłowska, M.łg. 2005: HCV: immune response and its modifiers in clinical development Przeglad Epidemiologiczny 59(2): 519-523
Bach, D.; Romics, I.; Rüssel, C. 1992: Clinical experience with BCG immune prevention in superficial bladder cancer Der Urologe. Ausg. a 31(5): 296-301
Ericson, K.J.; Murthy, P.B.; Bryk, D.J.; Ramkumar, R.R.; Broughman, J.R.; Khanna, A.; Mian, O.Y.; Campbell, S.C. 2019: Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer Clinical Advances in Hematology and Oncology: H&o 17(12): 697-707
Tsukagoshi, S. 2003: ImmuCyst intravesical (freeze-dried preparation made from the connaught strain of Bacillus Calmette Guérin) for the treatment of superficial bladder cancer and carcinoma in situ of urinary bladder Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(7): 1027-1038
Del Zingaro, M.; Bruno, R.; Nunzi, E.; Porena, M.; Mearini, L. 2016: First and second transurethral resections in intermediate-high risk bladder cancer: impact of the surgeon's volume on the recurrence and progression of primary bladder cancer Minerva Urologica e Nefrologica 68(2): 194-203
Ackermann, R. 1988: Biological response modifiers in renal cancer Progress in Clinical and Biological Research 269: 313-328
Quesada, J.R. 1989: Biologic response modifiers in cancer therapy: a review Texas Medicine 85(11): 42-47
Mommsen, S.; Jakobsen, A.; Sell, A. 1989: Quality of life in patients with advanced bladder cancer. a randomized study comparing cystectomy and irradiation--the Danish Bladder Cancer Study Group (DAVECA protocol 8201) Scandinavian Journal of Urology and Nephrology. Supplementum 125: 115-120
Aihara, R.; Sato, K.; Sasaki, K.; Hosaka, Y.; Narita, T. 1985: Pre and postoperative nursing of patients with bladder cancer. Nursing of a patient in the terminal stage of bladder cancer with poor prognosis Nursing Technique 31(11): 1492-1497
Baxter, A. 1999: Bladder cancer: its diagnosis and treatment Nursing Times 95(41): 42-44
Novak, R. 1979: A modern treatment of the bladder cancer Lijecnicki Vjesnik 101(7): 393-394
Fryjordet, A. 1974: Treatment planning in cancer of the bladder Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 94(31): 2164-2165
Novak, M.J.; Donley, T.G. 2002: Using host response modifiers in the treatment of periodontal disease Practical Procedures and Aesthetic Dentistry: Ppad 14(9): Suppl 3
Staehler, W. 1971: Surgical treatment possibilities in bladder cancer Wiener Medizinische Wochenschrift 121(47): 841-843
Lance, R.S.; Grossman, H.Barton. 2003: Recent developments in the treatment of bladder cancer Advances in Experimental Medicine and Biology 539(Pt A): 3-14
Steineck, G.; Wijkström, H.; Borghede, G. 1994: Treatment of bladder cancer with cytostatic agents Lakartidningen 91(5): 397-404